It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Lung cancer (LC) and pulmonary tuberculosis (TB) are the deadliest neoplastic and bacterial infectious diseases worldwide, respectively. Clinicians and pathologists have long discussed the co-existence of LC and TB, and several epidemiologic studies have presented evidence indicating that TB could be associated with the development of LC, particularly adenocarcinoma. Nonetheless, this data remains controversial, and the mechanism which could underlie the association remains largely unexplored. Some bioinformatic studies have shown that human cancer biopsies have a very high frequency of bacterial DNA integration; since Mycobacterium Tuberculosis (MTb) is an intracellular pathogen, it could play an active role in the cellular transformation. Our group performed an exploratory study in a cohort of 88 LC patients treated at the Instituto Nacional de Cancelorogía (INCan) of Mexico City to evaluate the presence of MTb DNA in LC tissue specimens. For the first time, our results show the presence of the MTb IS6110 transposon in 40.9% (n = 36/88) of patients with lung adenocarcinomas. Additionally, through in-situ PCR we identified the presence of IS6110 in the nuclei of tumor cells. Furthermore, shotgun sequencing from two samples identified traces of MTb genomes present in tumor tissue, suggesting that similar Mtb strains could be infecting both patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Instituto Nacional de Cancerología (INCan), Thoracic Oncology Unit and Laboratory of Personalized Medicine, Mexico City, Mexico (GRID:grid.419167.c) (ISNI:0000 0004 1777 1207)
2 Universidad Nacional Autonoma de México, Departamento de Microbiología Molecular, Instituto de Biotecnología, Cuernavaca, Mexico (GRID:grid.9486.3) (ISNI:0000 0001 2159 0001)
3 Instituto Nacional de Ciencias Médicas y NutriciónSalvador Zubirán, Experimental Pathology Laboratory, Department of Pathology, Mexico City, Mexico (GRID:grid.416850.e) (ISNI:0000 0001 0698 4037)
4 INCan, Department of Pathology, Mexico City, Mexico (GRID:grid.416850.e)
5 Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia (GRID:grid.9486.3); Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia (GRID:grid.512352.2); Universidad El Bosque, Molecular Oncology and Biology Systems Research Group (FOX-G/ONCOLGroup), Bogotá, Colombia (GRID:grid.412195.a) (ISNI:0000 0004 1761 4447)
6 Instituto Nacional de Cancerología (INCan), Translational Medicine Laboratory, Mexico City, Mexico (GRID:grid.419167.c) (ISNI:0000 0004 1777 1207)